相似文献
1
Feeding the wrath with myelin.
Trends Immunol. 2024 Oct;45(10):729-731. doi: 10.1016/j.it.2024.09.004. Epub 2024 Sep 27.
2
Lipid-Laden Macrophages Recycle Myelin to Feed Glioblastoma.
Cancer Res. 2024 Nov 15;84(22):3712-3714. doi: 10.1158/0008-5472.CAN-24-3362.
3
Macrophage-mediated myelin recycling fuels brain cancer malignancy.
Cell. 2024 Sep 19;187(19):5336-5356.e30. doi: 10.1016/j.cell.2024.07.030. Epub 2024 Aug 12.
4
STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma.
Dev Cell. 2025 Jun 23;60(12):1751-1767.e9. doi: 10.1016/j.devcel.2025.01.014. Epub 2025 Feb 10.
5
In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy.
Proc Natl Acad Sci U S A. 2025 Jul 22;122(29):e2426724122. doi: 10.1073/pnas.2426724122. Epub 2025 Jul 14.
6
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages.
Cancer Commun (Lond). 2025 Mar 14. doi: 10.1002/cac2.70016.
7
The Epithelial-to-Mesenchymal Transition-Like Process in Glioblastoma: An Updated Systematic Review and In Silico Investigation.
Med Res Rev. 2017 Mar;37(2):271-313. doi: 10.1002/med.21408. Epub 2016 Sep 12.
8
EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis.
Cell Death Dis. 2025 Jun 17;16(1):453. doi: 10.1038/s41419-025-07771-1.
9
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor-Associated Macrophages and Microglia to Treat Glioblastoma.
CPT Pharmacometrics Syst Pharmacol. 2025 Jul;14(7):1156-1167. doi: 10.1002/psp4.70033. Epub 2025 May 9.
10
Endocannabinoid Receptor 2 Function is Associated with Tumor-Associated Macrophage Accumulation and Increases in T Cell Number to Initiate a Potent Antitumor Response in a Syngeneic Murine Model of Glioblastoma.
Cannabis Cannabinoid Res. 2024 Dec;9(6):1524-1536. doi: 10.1089/can.2024.0063. Epub 2024 Jun 18.
本文引用的文献
1
Macrophage-mediated myelin recycling fuels brain cancer malignancy.
Cell. 2024 Sep 19;187(19):5336-5356.e30. doi: 10.1016/j.cell.2024.07.030. Epub 2024 Aug 12.
2
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Nat Commun. 2021 Nov 26;12(1):6938. doi: 10.1038/s41467-021-26940-2.
3
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
Cell. 2019 Aug 8;178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. Epub 2019 Jul 18.
4
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.
5
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.
6
Clonal evolution of glioblastoma under therapy.
Nat Genet. 2016 Jul;48(7):768-76. doi: 10.1038/ng.3590. Epub 2016 Jun 6.
7
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Genome Res. 2015 Mar;25(3):316-27. doi: 10.1101/gr.180612.114. Epub 2015 Feb 3.
8
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Science. 2014 Jan 10;343(6167):189-193. doi: 10.1126/science.1239947. Epub 2013 Dec 12.
9
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.
10
Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors.
J Neurosurg. 1979 Mar;50(3):305-11. doi: 10.3171/jns.1979.50.3.0305.
Zotero 插件